A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases.
- 1 opens in JClub
Linafexor, a pulsatile FXR agonist, effectively treats bile acid-related liver diseases by mimicking natural bile acid signaling cycles, avoiding toxicity linked to continuous activation.
- Why it matters: Continuous activation of nuclear receptors often reduces drug efficacy and causes toxicity, creating a need for therapies that better align with physiological signaling patterns to improve safety and effectiveness.
- What they did: A first-principles drug design approach was used to develop linafexor, a potent FXR agonist engineered for rapid clearance, enabling pulsatile activation that reflects endogenous bile acid dynamics, tested across multiple preclinical models and phase 1 trials.
- The result: Linafexor demonstrated robust efficacy without adverse effects, maintaining cyclic FXR signaling, preventing receptor downregulation, and establishing activation duration as key to a favorable therapeutic index, paving the way for clinical use.